These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
206 related items for PubMed ID: 17419745
1. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial. Jäger G, Quehenberger F, Linkesch W, Neumeister P. Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745 [No Abstract] [Full Text] [Related]
2. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411 [Abstract] [Full Text] [Related]
4. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, Fernández de Sevilla A. Haematologica; 2002 Nov 01; 87(11):1229-30. PubMed ID: 12414357 [Abstract] [Full Text] [Related]
5. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S. Clin Cancer Res; 2007 Oct 01; 13(19):5784-9. PubMed ID: 17908969 [Abstract] [Full Text] [Related]
8. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma. Ghielmini M. Cancer Treat Rev; 2005 Dec 01; 31(8):644-7. PubMed ID: 16289339 [No Abstract] [Full Text] [Related]
9. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study. Van Oers MH, Hagenbeek A, Van Glabbeke M, Teodorovic I. Ann Hematol; 2002 Oct 01; 81(10):553-7. PubMed ID: 12424535 [No Abstract] [Full Text] [Related]
10. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma]. Ogura M. Rinsho Ketsueki; 2006 Jun 01; 47(6):495-512. PubMed ID: 16862978 [No Abstract] [Full Text] [Related]
11. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL. Br J Haematol; 2009 Feb 01; 144(4):524-30. PubMed ID: 19036081 [Abstract] [Full Text] [Related]
12. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Bermúdez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Haematologica; 2000 Aug 01; 85(8):894-5. PubMed ID: 10942955 [No Abstract] [Full Text] [Related]
13. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients. Janikova A, Koristek Z, Vinklarkova J, Pavlik T, Sticha M, Navratil M, Kral Z, Vasova I, Mayer J. Exp Hematol; 2009 Nov 01; 37(11):1266-73. PubMed ID: 19654036 [Abstract] [Full Text] [Related]
14. Novel treatment strategies in follicular lymphoma. Buske C, Dreyling H, Unterhalt M, Hiddemann W. Ann Hematol; 2004 Nov 01; 83 Suppl 1():S72. PubMed ID: 15124680 [Abstract] [Full Text] [Related]
15. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology Group. J Clin Oncol; 2006 Sep 01; 24(25):4143-9. PubMed ID: 16896003 [Abstract] [Full Text] [Related]
16. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma. Clin Adv Hematol Oncol; 2006 Jul 01; 4(7):536-8. PubMed ID: 17147240 [No Abstract] [Full Text] [Related]
17. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G. J Clin Oncol; 2008 Oct 01; 26(28):4579-86. PubMed ID: 18662969 [Abstract] [Full Text] [Related]
18. High-dose therapy for follicular lymphoma revisited: not if, but when? Lister TA. J Clin Oncol; 2003 Nov 01; 21(21):3894-6. PubMed ID: 14517186 [No Abstract] [Full Text] [Related]
19. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, Sill H. Eur J Haematol; 2002 Jul 01; 69(1):21-6. PubMed ID: 12270058 [Abstract] [Full Text] [Related]
20. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Br J Haematol; 2008 Feb 01; 140(4):411-9. PubMed ID: 18162120 [Abstract] [Full Text] [Related] Page: [Next] [New Search]